NCT02649686View on ClinicalTrials.gov

Durvalumab in Patients With HER-2 Positive Metastatic Breast Cancer Receiving Trastuzumab

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

May 17, 2016

Primary Completion Date

September 25, 2017

Study Completion Date

November 12, 2019

Conditions
Metastatic Breast Cancer
Interventions
DRUG

Durvalumab

DRUG

Trastuzumab

Trial Locations (3)

V5Z 4E6

BCCA - Vancouver Cancer Centre, Vancouver

K1H 8L6

Ottawa Hospital Research Institute, Ottawa

M5G 2M9

University Health Network, Toronto

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Canadian Cancer Trials Group

NETWORK